Peanut Allergy
100
8
16
60
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Published Results
34 trials with published results (34%)
Research Maturity
60 completed trials (60% of total)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
8.0%
8 terminated out of 100 trials
88.2%
+1.7% vs benchmark
15%
15 trials in Phase 3/4
57%
34 of 60 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 60 completed trials
Clinical Trials (100)
Peanut Oral Induction Tolerance in Peanut's Allergic Teenagers
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
Safety of MOON101 for the Treatment of Peanut Allergy
Efficacy of Tezepelumab in Peanut Oral Immunotherapy
UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies
Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)
Using Commonly Available Food Products To Treat Food Allergy
Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy
Investigating Modified Protocols of Oral Immunotherapy to Validate Efficacy and Safety
Evaluating the Safety and Efficacy of Oral Encapsulated Fecal Microbiota Transplant in Peanut Allergic Patients
Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants
Food Oral Immunotherapy for Peanut Allergy
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy
Comparing Standard and Autoclaved Peanut Oral Immunotherapy in People With Peanut Allergy
Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children
High and Low Dose Oral Peanut Immunotherapy - Comparison of Efficacy and Safety
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IGNX001
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen OIT in Food Allergic Participants